Intrathecal Non-preservative-free Morphine With Bupivacaine Versus Intrathecal Bupivacaine Alone for Analgesia in Unilateral Inguinal Hernia Repair Surgeries
NCT ID: NCT06319859
Last Updated: 2025-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
50 participants
INTERVENTIONAL
2024-08-03
2025-11-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intrathecal Morphine for Inguinal Hernia Repair.
NCT02001948
Dexmedetomidine vs Ketamine as Adjuvants to Bupivacaine in Transversus Abdominus Plane Block in Inguinal Hernioplasty
NCT07194694
The Analgesic Efficacy of Two Bupivacaine Concentrations for Combined Ilioinguinal and Iliohypogastric Nerve Block in Postherniorrhaphy Pain
NCT05687981
Analgesic Effect of Bupivacaine Plus Ketamine Versus Bupivacaine Alone in Transversalis Fascia Plane Block
NCT06935669
Topical Ketamine Versus Caudal Ketamine for Postoperative Analgesia in Children Undergoing Inguinal Herniotomy
NCT02462174
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally
Morphine
The patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally
Group B
patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
Placebo
The patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Morphine
The patients will receive 0.1 mg morphine with 15 mg heavy bupivacaine intrathecally
Placebo
The patients will receive 15 mg heavy bupivacaine with 0.1 ml saline intrathecally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both genders.
* ASA I and II class.
Exclusion Criteria
* Known local anesthetic (LA) allergy.
* Skin lesions or infections at the site of needle insertion.
* Contraindications to spinal anesthesia.
* Failure of spinal anesthesia.
* ASA III and VI class.
* Central or peripheral neuropathies.
* Severe respiratory or cardiac diseases.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cairo University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AbdElKhalik Mahmoud Shaban
Lecturer of anaesthesia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr Alaini hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-72-2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.